Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

Immune checkpoints blockade (ICB) is a viable anti-cancer strategy. Here the authors show that nuclear receptor NR2F6 acts as an immune checkpoint in T cells and, using mouse models and human T cells, they show NR2F6 inhibition might improve current ICB therapy or work as an alternative therapeutic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Victoria Klepsch, Natascha Hermann-Kleiter, Patricia Do-Dinh, Bojana Jakic, Anne Offermann, Mirjana Efremova, Sieghart Sopper, Dietmar Rieder, Anne Krogsdam, Gabriele Gamerith, Sven Perner, Alexandar Tzankov, Zlatko Trajanoski, Dominik Wolf, Gottfried Baier
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/6708fd1e3e99478a95dc46aa8093f81c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6708fd1e3e99478a95dc46aa8093f81c
record_format	dspace
spelling	oai:doaj.org-article:6708fd1e3e99478a95dc46aa8093f81c2021-12-02T17:31:12ZNuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade10.1038/s41467-018-04004-22041-1723https://doaj.org/article/6708fd1e3e99478a95dc46aa8093f81c2018-04-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-04004-2https://doaj.org/toc/2041-1723Immune checkpoints blockade (ICB) is a viable anti-cancer strategy. Here the authors show that nuclear receptor NR2F6 acts as an immune checkpoint in T cells and, using mouse models and human T cells, they show NR2F6 inhibition might improve current ICB therapy or work as an alternative therapeutic strategy.Victoria KlepschNatascha Hermann-KleiterPatricia Do-DinhBojana JakicAnne OffermannMirjana EfremovaSieghart SopperDietmar RiederAnne KrogsdamGabriele GamerithSven PernerAlexandar TzankovZlatko TrajanoskiDominik WolfGottfried BaierNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Victoria Klepsch Natascha Hermann-Kleiter Patricia Do-Dinh Bojana Jakic Anne Offermann Mirjana Efremova Sieghart Sopper Dietmar Rieder Anne Krogsdam Gabriele Gamerith Sven Perner Alexandar Tzankov Zlatko Trajanoski Dominik Wolf Gottfried Baier Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
description	Immune checkpoints blockade (ICB) is a viable anti-cancer strategy. Here the authors show that nuclear receptor NR2F6 acts as an immune checkpoint in T cells and, using mouse models and human T cells, they show NR2F6 inhibition might improve current ICB therapy or work as an alternative therapeutic strategy.
format	article
author	Victoria Klepsch Natascha Hermann-Kleiter Patricia Do-Dinh Bojana Jakic Anne Offermann Mirjana Efremova Sieghart Sopper Dietmar Rieder Anne Krogsdam Gabriele Gamerith Sven Perner Alexandar Tzankov Zlatko Trajanoski Dominik Wolf Gottfried Baier
author_facet	Victoria Klepsch Natascha Hermann-Kleiter Patricia Do-Dinh Bojana Jakic Anne Offermann Mirjana Efremova Sieghart Sopper Dietmar Rieder Anne Krogsdam Gabriele Gamerith Sven Perner Alexandar Tzankov Zlatko Trajanoski Dominik Wolf Gottfried Baier
author_sort	Victoria Klepsch
title	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
title_short	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
title_full	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
title_fullStr	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
title_full_unstemmed	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
title_sort	nuclear receptor nr2f6 inhibition potentiates responses to pd-l1/pd-1 cancer immune checkpoint blockade
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/6708fd1e3e99478a95dc46aa8093f81c
work_keys_str_mv	AT victoriaklepsch nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT nataschahermannkleiter nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT patriciadodinh nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT bojanajakic nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT anneoffermann nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT mirjanaefremova nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT sieghartsopper nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT dietmarrieder nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT annekrogsdam nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT gabrielegamerith nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT svenperner nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT alexandartzankov nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT zlatkotrajanoski nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT dominikwolf nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade AT gottfriedbaier nuclearreceptornr2f6inhibitionpotentiatesresponsestopdl1pd1cancerimmunecheckpointblockade
_version_	1718380675886743552

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

Ejemplares similares